A mum who lost three stone on weight loss drug Mounjaro says it wasn't "worth it" after it caused hair loss and left her ...

The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...

A simple bouquet of flowers, specifically lilies brightening up the kitchen, ended in heartbreak for one woman who lost her 3 ...

President Donald Trump’s tariffs have two primary objectives. One is to rebalance the world trade order, which he believes is ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...